Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Novartis Pharmaceuticals Corporation v. MSN Pharmaceuticals Inc., et al
Case Number:
1:22-cv-01395
Court:
Nature of Suit:
Patent - Abbreviated New Drug Application(ANDA)
Judge:
Firms
- Heyman Enerio
- McCarter & English
- Potter Anderson
- Smith Katzenstein
- Stamoulis & Weinblatt
- Venable LLP
Companies
Sectors & Industries:
-
December 05, 2024
IP Forecast: PTAB To Hear Pfizer Fight Over COVID-19 Patents
Pfizer heads to an administrative board at the U.S. Patent and Trademark Office next week to argue Moderna should not have been issued patents covering "a basic idea" like using mRNA to fight the COVID-19 virus. Here's a spotlight on that case — plus all the other major intellectual property matters on deck in the coming week.
-
December 04, 2024
Novartis Fails To Stop Generic Drug Release At Fed. Circ.
Novartis could not persuade Federal Circuit judges to grant an injunction Wednesday protecting its blockbuster heart failure medication from facing generic competition, with the appeals court backing a Delaware federal judge's opinion that it was unlikely that one of the generic drug's ingredients is "amorphous."
-
September 29, 2023
Generic Cos. Must Face IP Claims Over Novartis Blockbuster
A Delaware federal judge on Friday cleared Novartis Pharmaceuticals Corp. to proceed with infringement litigation against a pair of companies aiming to sell generic versions of its blockbuster cardiovascular drug Entresto.
-
October 25, 2022
Novartis Sues Viatris, Others In New IP Fight Over Heart Drug
Amid Novartis' ongoing multidistrict patent litigation against generic-drug makers over the heart medication Entresto, the Swiss pharmaceutical giant has now targeted Viatris and others in a new Delaware federal court infringement suit over another Entresto patent.